摘要
目的探讨弥漫性大B细胞淋巴瘤(DLBCL)患者中不同组蛋白去乙酰化酶3(HDAC3)水平与临床病理特征及预后的相关性,并评估HDAC3作为预后生物标志物的潜力。方法研究纳入86例DLBCL患者,采用免疫组化染色法检测HDAC3蛋白表达,并运用ROC曲线与Logistic回归分析等评估其与临床病理特征及预后的关联。结果在DLBCL患者中,47例(54.65%)预后不良,39例(45.35%)预后良好。HDAC3表达水平在肿瘤组织中显著高于正常B淋巴细胞(P<0.05),并以4.50为截断值。高水平HDAC3表达(≥5分)是预后不良的独立预测因素(P<0.05)。此外,晚期Ann Arbor分期、高国际预后指数(IPI)和美国东部肿瘤协作组体力状态标准评分(ECOG PS)同样是预后不良的独立预测因素(P<0.05)。结论HDAC3高水平表达与DLBCL患者的不良预后密切相关,且HDAC3可能作为DLBCL预后评估的潜在生物标志物。
Objective This study aimed to investigate the correlation between different levels of histone deacetylase 3(HDAC3)and the clinical pathological characteristics and prognosis in patients with Diffuse Large B-Cell Lymphoma(DLBCL),and to assess the potential of HDAC3 as a prognostic biomarker.Methods The study enrolled 86 patients with DLBCL,employed immunohistochemical staining to detect HDAC3 protein expression,and utilized receiver operating characteristic(ROC)curve and logistic regression analysis to assess its association with clinical pathological features and prognosis.Results In DLBCL patients,47 cases(54.65%)had poor prognosis,and 39 cases(45.35%)had good prognosis.The expression level of HDAC3 in tumor tissue was significantly higher than that in normal tissue(P<0.05),with a cutoff value of 4.50.High-level HDAC3 expression(≥5 points)is an independent predictor of poor prognosis(P<0.05).Additionally,advanced Ann Arbor stage,high international prognostic index(IPI),and Eastern Cooperative Oncology Group Performance Status scale(ECOG PS)scores are also independent predictors of poor prognosis(P<0.05).Conclusion Elevated HDAC3 levels were significantly linked to unfavorable outcomes in patients with DLBCL,suggesting that HDAC3 could potentially act as a biomarker for evaluating prognosis in DLBCL.
作者
冶俊玲
郭新建
苟笑丹
郑小影
巩雪
韩静绮
YE Jun-ling;GUO Xin-jian;GOU Xiao-dan;ZHENG Xiao-ying;GONG Xue;HAN Jing-qi(Department of Pathology,Qinghai University Affiliated Hospital,Xining,Qinghai 810000,China)
出处
《诊断病理学杂志》
2025年第6期659-665,共7页
Chinese Journal of Diagnostic Pathology
